ArticleTranslational cancer research2024
Nomogram for predicting the early death of patients with stage IV ovarian cancer: a retrospective analysis of the SEER database.
Article in Translational cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic significance of chemotherapy response score in predicting outcomes for high-grade serous ovarian carcinoma patients undergoing neoadjuvant chemotherapy.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer is a major health problem for women all over the world and tends to progress to advanced stages. Therefore, it is important to predict the early survival of patients with advanced ovarian cancer. The purpose of this study is to assist clinicians in predicting the short-term prognosis of patients with stage IV ovarian cancer in order to make optimal medical decisions. Methods: A retrospective analysis was conducted on data from the Surveillance, Epidemiology, and End Results database, involving 3,077 patients with stage IV ovarian cancer. Univariate and multivariate logistic regression analyses were performed to identify risk factors. Using R software, relevant predictive models were constructed. The calibration, discrimination, and clinical utility of these models were assessed in a validation cohort. Results: A nomogram model was developed utilizing four independent risk factors to predict the probability of early death in patients with stage IV ovarian cancer. The model exhibited satisfactory discrimination in both the training cohort (area under the receiver operating characteristic curve =0.816) and the validation cohort (area under the receiver operating characteristic curve =0.827). The calibration curve demonstrated a high level of predictive accuracy for the model. Furthermore, the decision curve analysis indicated that the nomogram holds clinical utility and offers a net benefit to patients within certain limitations. The predictive effectiveness of the nomogram was verified by the Kaplan-Meier survival curve. Conclusions: We have successfully developed a nomogram and risk classification system to accurately predict the probability of early death in patients with stage IV ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.